Logo image of GANX

GAIN THERAPEUTICS INC (GANX) Stock Fundamental Analysis

NASDAQ:GANX - Nasdaq - US36269B1052 - Common Stock - Currency: USD

1.585  -0.03 (-1.55%)

After market: 1.6195 +0.03 (+2.18%)

Fundamental Rating

1

Taking everything into account, GANX scores 1 out of 10 in our fundamental rating. GANX was compared to 558 industry peers in the Biotechnology industry. GANX may be in some trouble as it scores bad on both profitability and health. GANX is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year GANX has reported negative net income.
GANX had a negative operating cash flow in the past year.
In the past 5 years GANX always reported negative net income.
GANX had a negative operating cash flow in each of the past 5 years.
GANX Yearly Net Income VS EBIT VS OCF VS FCFGANX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2018 2019 2020 2021 2022 2023 2024 -5M -10M -15M -20M

1.2 Ratios

GANX's Return On Assets of -168.36% is on the low side compared to the rest of the industry. GANX is outperformed by 86.56% of its industry peers.
GANX has a Return On Equity of -278.10%. This is in the lower half of the industry: GANX underperforms 71.33% of its industry peers.
Industry RankSector Rank
ROA -168.36%
ROE -278.1%
ROIC N/A
ROA(3y)-120.33%
ROA(5y)-86.78%
ROE(3y)-182.77%
ROE(5y)-129.19%
ROIC(3y)N/A
ROIC(5y)N/A
GANX Yearly ROA, ROE, ROICGANX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2018 2019 2020 2021 2022 2023 2024 0 200 -200 400 600

1.3 Margins

GANX does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
GANX Yearly Profit, Operating, Gross MarginsGANX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2018 2019 2020 2021 2022 2023 2024 -10K -20K -30K -40K

More info and screens

2

2. Health

2.1 Basic Checks

GANX does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, GANX has more shares outstanding
The number of shares outstanding for GANX has been increased compared to 5 years ago.
The debt/assets ratio for GANX is higher compared to a year ago.
GANX Yearly Shares OutstandingGANX Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 2024 5M 10M 15M 20M 25M
GANX Yearly Total Debt VS Total AssetsGANX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 2024 10M 20M 30M

2.2 Solvency

Based on the Altman-Z score of -8.28, we must say that GANX is in the distress zone and has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of -8.28, GANX is doing worse than 69.18% of the companies in the same industry.
GANX has a Debt/Equity ratio of 0.04. This is a healthy value indicating a solid balance between debt and equity.
GANX has a Debt to Equity ratio of 0.04. This is in the lower half of the industry: GANX underperforms 61.83% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.04
Debt/FCF N/A
Altman-Z -8.28
ROIC/WACCN/A
WACC9.69%
GANX Yearly LT Debt VS Equity VS FCFGANX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2018 2019 2020 2021 2022 2023 2024 0 10M -10M 20M 30M

2.3 Liquidity

A Current Ratio of 2.97 indicates that GANX has no problem at all paying its short term obligations.
Looking at the Current ratio, with a value of 2.97, GANX is doing worse than 65.05% of the companies in the same industry.
GANX has a Quick Ratio of 2.97. This indicates that GANX is financially healthy and has no problem in meeting its short term obligations.
The Quick ratio of GANX (2.97) is worse than 63.62% of its industry peers.
Industry RankSector Rank
Current Ratio 2.97
Quick Ratio 2.97
GANX Yearly Current Assets VS Current LiabilitesGANX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 2024 10M 20M 30M

More info and screens

1

3. Growth

3.1 Past

GANX shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 45.22%, which is quite impressive.
Looking at the last year, GANX shows a very negative growth in Revenue. The Revenue has decreased by -100.00% in the last year.
EPS 1Y (TTM)45.22%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%27.27%
Revenue 1Y (TTM)-100%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

Based on estimates for the next years, GANX will show a quite strong growth in Earnings Per Share. The EPS will grow by 10.02% on average per year.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y30.71%
EPS Next 2Y9.52%
EPS Next 3Y6.48%
EPS Next 5Y10.02%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
GANX Yearly Revenue VS EstimatesGANX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2018 2019 2020 2021 2022 2023 2029 2030 2031 2032 100M 200M 300M
GANX Yearly EPS VS EstimatesGANX Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 1 -1 2 3

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

GANX reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for GANX. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
GANX Price Earnings VS Forward Price EarningsGANX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
GANX Per share dataGANX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.2 -0.2 -0.4 -0.6 -0.8

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y9.52%
EPS Next 3Y6.48%

More info and screens

0

5. Dividend

5.1 Amount

GANX does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

GAIN THERAPEUTICS INC

NASDAQ:GANX (7/18/2025, 8:00:01 PM)

After market: 1.6195 +0.03 (+2.18%)

1.585

-0.03 (-1.55%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)05-14 2025-05-14/bmo
Earnings (Next)08-07 2025-08-07
Inst Owners9.53%
Inst Owner Change0%
Ins Owners4.42%
Ins Owner Change0%
Market Cap46.85M
Analysts84.62
Price Target8.67 (447%)
Short Float %0.89%
Short Ratio0.89
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)31.83%
Min EPS beat(2)22.48%
Max EPS beat(2)41.18%
EPS beat(4)3
Avg EPS beat(4)-3.99%
Min EPS beat(4)-105.88%
Max EPS beat(4)41.18%
EPS beat(8)4
Avg EPS beat(8)-13.95%
EPS beat(12)6
Avg EPS beat(12)-8.59%
EPS beat(16)8
Avg EPS beat(16)-12.45%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)6.25%
PT rev (3m)6.25%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-1.41%
EPS NY rev (1m)11.76%
EPS NY rev (3m)20.89%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)-100%
Revenue NY rev (3m)-100%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 6.38
P/tB 6.5
EV/EBITDA N/A
EPS(TTM)-0.86
EYN/A
EPS(NY)-0.74
Fwd EYN/A
FCF(TTM)-0.64
FCFYN/A
OCF(TTM)-0.64
OCFYN/A
SpS0
BVpS0.25
TBVpS0.24
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -168.36%
ROE -278.1%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-120.33%
ROA(5y)-86.78%
ROE(3y)-182.77%
ROE(5y)-129.19%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score1
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0.04
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 26.75%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.97
Quick Ratio 2.97
Altman-Z -8.28
F-Score1
WACC9.69%
ROIC/WACCN/A
Cap/Depr(3y)81.72%
Cap/Depr(5y)179.04%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)45.22%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%27.27%
EPS Next Y30.71%
EPS Next 2Y9.52%
EPS Next 3Y6.48%
EPS Next 5Y10.02%
Revenue 1Y (TTM)-100%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y8.55%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-0.08%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-0.04%
OCF growth 3YN/A
OCF growth 5YN/A